- Home
- AMTB vs PHAT Comparison
AMTB vs PHAT Comparison
Compare AMTB & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMTB
- PHAT
- Stock Information
- Founded
- AMTB 1979
- PHAT 2018
- Country
- AMTB United States
- PHAT United States
- Employees
- AMTB N/A
- PHAT N/A
- Industry
- AMTB Major Banks
- PHAT Biotechnology: Pharmaceutical Preparations
- Sector
- AMTB Finance
- PHAT Health Care
- Exchange
- AMTB Nasdaq
- PHAT Nasdaq
- Market Cap
- AMTB 723.8M
- PHAT 1.2B
- IPO Year
- AMTB N/A
- PHAT 2019
- Fundamental
- Price
- AMTB $21.20
- PHAT $18.54
- Analyst Decision
- AMTB Hold
- PHAT Strong Buy
- Analyst Count
- AMTB 6
- PHAT 4
- Target Price
- AMTB $25.40
- PHAT $22.50
- AVG Volume (30 Days)
- AMTB 78.6K
- PHAT 1.0M
- Earning Date
- AMTB 10-17-2024
- PHAT 11-07-2024
- Dividend Yield
- AMTB 1.67%
- PHAT N/A
- EPS Growth
- AMTB N/A
- PHAT N/A
- EPS
- AMTB 0.61
- PHAT N/A
- Revenue
- AMTB $327,309,000.00
- PHAT $9,918,000.00
- Revenue This Year
- AMTB N/A
- PHAT $6,512.02
- Revenue Next Year
- AMTB $5.12
- PHAT $292.78
- P/E Ratio
- AMTB $35.49
- PHAT N/A
- Revenue Growth
- AMTB 8.52
- PHAT N/A
- 52 Week Low
- AMTB $16.63
- PHAT $6.07
- 52 Week High
- AMTB $27.00
- PHAT $19.68
- Technical
- Relative Strength Index (RSI)
- AMTB 50.09
- PHAT 78.28
- Support Level
- AMTB $19.92
- PHAT $16.76
- Resistance Level
- AMTB $22.17
- PHAT $19.68
- Average True Range (ATR)
- AMTB 0.58
- PHAT 1.08
- MACD
- AMTB 0.01
- PHAT 0.25
- Stochastic Oscillator
- AMTB 51.19
- PHAT 90.53
About AMTB Amerant Bancorp Inc.
Amerant Bancorp Inc is a bank holding company. Through its bank, it provides individuals and businesses deposit, credit, investment, wealth management, and fiduciary services, both in the United States and to select international customers. The bank also provides banking services through traditional channels, such as banking centers and ATMs, as well as via secure websites, mobile devices, and telephones.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.